Sun Pharmaceutical Industries has announced a landmark $11.75 billion acquisition of Organon & Co., marking a transformative move in the global pharmaceutical landscape. This strategic deal strengthens Sun Pharma's portfolio in women's health and biosimilars, enabling the company to expand its market reach and competitiveness. The acquisition is expected to create substantial shareholder value while establishing Sun Pharma as a major player in specialized therapeutic areas, driving long-term growth through product diversification and enhanced innovation capabilities.

Summary auto-generated by AI from the original publisher's content. Editorial standards.